SRR2779183
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.500
- IL6_JAK_STAT3_SIGNALING+0.500
- INFLAMMATORY_RESPONSE+0.500
- TNFA_SIGNALING_VIA_NFKB+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- COMPLEMENT+0.300
- IL2_STAT5_SIGNALING+0.300
- ANGIOGENESIS+0.200
Top 10 suppressed
- MYC_TARGETS_V1-0.600
- OXIDATIVE_PHOSPHORYLATION-0.600
- PROTEIN_SECRETION-0.500
- MYC_TARGETS_V2-0.400
- ADIPOGENESIS-0.300
- ANDROGEN_RESPONSE-0.300
- DNA_REPAIR-0.300
- E2F_TARGETS-0.300
- FATTY_ACID_METABOLISM-0.300
- G2M_CHECKPOINT-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | sclc55A_S50.txt | — | cohortMD2 | 0.927 |
| 2 | e5b29c06-2ed0-4913-bf24-5bfde047defc | — | — | 0.924 |
| 3 | TCGA-D8-A73U-01A-11R-A33J-07 | — | D | 0.917 |
| 4 | SRR10842349 | — | — | 0.909 |
| 5 | sclcA055A_S52.txt | — | cohortMD2 | 0.907 |
| 6 | TCGA-44-A47G-01A-21R-A24H-07 | — | cohortA1 | 0.905 |
| 7 | TCGA-LD-A9QF-01A-32R-A41B-07 | — | D | 0.904 |
| 8 | BS_B0SVFK4P | pleomorphic xanthoastrocytoma(PXA) | — | 0.904 |
| 9 | SRR35579837 | — | D | 0.900 |
| 10 | MDT-AP-0379 | Med | Medulloblastoma | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |